Compare Abbott Laboratories (ABT) vs Delta Air Lines, Inc. (DAL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Delta Air Lines, Inc. — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while Delta Air Lines, Inc. trades at $87.23 (market cap $58.23B). The key difference: Abbott Laboratories is far larger — about 2.9× Delta Air Lines, Inc.'s market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | DAL | |
|---|---|---|
Market Cap | $166.94B | $58.23B |
Sector | Health | Industrials |
52-Week High | $136.62 | $93.66 |
52-Week Low | $82.57 | $50.52 |
Enterprise Value | $193.69B | $73.48B |
Dividend Yield | 2.63% | 0.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Delta Air Lines (DAL) trades at $88.63, down 4.44% today, but maintains strong fundamentals with consistent earnings beats and improving cash flow. The stock shows bullish technical signals with moving averages supporting upward momentum, while trading near key support at $88. Analysts remain overwhelmingly positive with 81% buy ratings and a $105.36 consensus target, representing 19% upside potential from current levels.
DAL presents a compelling investment case with attractive valuation multiples (P/E 13.38, P/S 0.92) and robust profitability (ROE 24.99%). However, investors face risks from fuel price volatility, labor cost pressures, and cyclical industry exposure. The upcoming Q2 earnings report on July 10 will be critical for validating current momentum and growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Delta Air Lines, Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Read more on DAL →
